Ser12
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser12  -  DAT (human)

Site Information
kCsVGLMssVVAPAK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451137

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 2 , 3 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 , 2 , 3 ) , EM4 (epithelial) ( 2 )

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 1 )
Kinases, in vitro:
CAMK2A (mouse) ( 2 )
Treatments:
autocamtide_inhibitory_peptide ( 1 ) , levamfetamine ( 1 ) , okadaic_acid ( 1 )

Downstream Regulation
Effects of modification on DAT:
activity, induced ( 2 , 3 )

References 

1

Karam CS, Sen N, Javitch JA (2017) Phospho-specific antibodies targeting the amino terminus of the human dopamine transporter. J Chem Neuroanat 83-84, 91-98
28571709   Curated Info

2

Fog JU, et al. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51, 417-29
16908408   Curated Info

3

Khoshbouei H, et al. (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2, E78
15024426   Curated Info